Hugel said Monday that it would participate in the 38th JP Morgan Conference to take place next Monday, giving updates on its business at home and abroad as well as its future vision. 

Hugel officials will present as part of the Emerging Markets track, which introduces major Asian companies at the conference, the company said. 

The main executives and officials of Hugel, including Representative Executive Officer Sohn Ji-hoon, will present on the competitiveness of the company, which has continued to grow in overseas markets as well as achieving the top spot in the domestic botulinum toxin and H.A. filler market. 

Also, the company said it would present on Hugel's unique success factors, from the H.E.L.F. academic forum to the development of consumer-oriented products.

The firm will also unveil a blueprint for becoming a global leader in medical esthetics.

With the acquisition of botulinum toxin in China and the entry of the B.L.A. into the U.S. and Europe, the company is expected to enter the big global market, expanding its overseas market.

It also said it would explain its R&D pipelines such as new-type development, open innovation strategy, and vision of corporate growth through expansion of production facilities.

"The company will present at the JP Morgan Healthcare Conference in recognition of the company's competitiveness and growth potential in domestic and overseas markets," the company said in a press release. "Conference participants will be introduced to the company's corporate value and its global growth strategy based on expertise and customer trust."